OR WAIT null SECS
Ocular Therapeutix Inc. is initiating a phase II clinical trial of OTX-TP2, a 2-month travoprost punctum plug for treating ocular hypertension and glaucoma.
Bedford, MA-Ocular Therapeutix Inc. is beginning a pilot phase II clinical trial to examine a 2-month sustained-release travoprost punctum plug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.
Researchers will enroll 20 patients (up to 40 eyes) at the Umhlanga Hospital Medical Centre and Netcare Alberlito Hospital in South Africa. Patients with documented ocular hypertension or open-angle glaucoma will be evaluated for reduction of IOP from baseline and retention of the plug through 2 months.
The initial travoprost punctum plug feasibility study, conducted at the Singapore National Eye Center and the National University Hospital in Singapore, examined efficacy of the technology over a 1-month duration.
“Having demonstrated proof of concept in our feasibility study, we have extended the length of drug delivery to 2 months for the pilot phase II trial,” said Amar Sawhney, PhD, president and chief executive officer of Ocular Therapeutix. “Extending treatment duration for the disease is a key milestone for our company’s path to commercialization.”
For more articles in this issue of Ophthalmology Times eReport, click here.